Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.47 |
| ▸ | VNN1 | O95497 | 8/20 | 0.45 |
| ▸ | LTC4S | Q16873 | 5/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9988347 | 0.81 | LTC4S (0.41) | P4HTMLTC4SIGFBP3KCNQ3KCNQ2 | |
| SCHEMBL237853 | 0.80 | P4HTM (0.46) | P4HTMVNN1LTC4SPPARAGCGR | |
| SCHEMBL239256 | 0.80 | LTC4S (0.65) | LTC4S | |
| SCHEMBL9988833 | 0.79 | LTC4S (0.49) | P4HTMVNN1LTC4SPPARAPPARG | |
| SCHEMBL236386 | 0.78 | P4HTM (0.48) | P4HTMVNN1LTC4SPPARA | |
| SCHEMBL2755493 | 0.77 | LTC4S (0.67) | LTC4S | |
| SCHEMBL237419 | 0.76 | RXRA (0.48) | P4HTMLTC4S | |
| SCHEMBL237439 | 0.74 | LTC4S (0.39) | P4HTMLTC4S | |
| SCHEMBL236679 | 0.74 | LTC4S (0.51) | P4HTMVNN1LTC4SGCGR | |
| SCHEMBL9988164 | 0.74 | LTC4S (0.45) | P4HTMLTC4SIGFBP3KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | P4HTM 403/4885VNN1 479/4885LTC4S 1/4885 |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | P4HTM 745/4885VNN1 502/4885LTC4S 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.